Literature DB >> 32551015

Synthesis and Evaluation of 11C- and 18F-Labeled SOAT1 Inhibitors as Macrophage Foam Cell Imaging Agents.

James R Hill1,2, Xia Shao2, Jay S Wright2, Jenelle Stauff2, Phillip S Sherman2, Janna Arteaga2, Ka Kit Wong2, Benjamin L Viglianti2,3, Peter J H Scott2, Allen F Brooks2.   

Abstract

PD-132301, an inhibitor of sterol O-acyltransferase 1 (SOAT1; also known as acyl-coenzyme A:cholesterol acyltransferase-1, ACAT1), is under clinical investigation for numerous adrenal disorders. Radiolabeled SOAT1 inhibitors could support drug discovery and help diagnose SOAT1-related disorders, such as atherosclerosis. We synthesized two radiolabeled SOAT1 inhibitors, [11C]PD-132301 and fluorine analogue [18F]1. Rat biodistribution studies were conducted with both agents and, as the most selective tracer, [11C]PD-132301 was advanced to preclinical positron emission tomography studies in (atherosclerotic) ApoE-/- mice. The uptake of [11C]PD-132301 in SOAT1-rich tissue warrants further investigation into the compound as an atherosclerosis and adrenal imaging agent.
Copyright © 2020 American Chemical Society.

Entities:  

Year:  2020        PMID: 32551015      PMCID: PMC7294710          DOI: 10.1021/acsmedchemlett.0c00127

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  21 in total

1.  A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma.

Authors:  David C Smith; Matthias Kroiss; Electron Kebebew; Mouhammed Amir Habra; Rashmi Chugh; Bryan J Schneider; Martin Fassnacht; Pegah Jafarinasabian; M Marian Ijzerman; Vivian H Lin; Pharis Mohideen; Aung Naing
Journal:  Invest New Drugs       Date:  2020-01-27       Impact factor: 3.850

2.  ATR-101, a Selective and Potent Inhibitor of Acyl-CoA Acyltransferase 1, Induces Apoptosis in H295R Adrenocortical Cells and in the Adrenal Cortex of Dogs.

Authors:  Christopher R LaPensee; Jacqueline E Mann; William E Rainey; Valentina Crudo; Stephen W Hunt; Gary D Hammer
Journal:  Endocrinology       Date:  2016-03-17       Impact factor: 4.736

3.  Differential toxicity of an inhibitor of mitochondrial respiration in canine hepatocytes and adrenocortical cell cultures.

Authors:  L A Vernetti; J R Macdonald; D G Pegg
Journal:  Toxicol In Vitro       Date:  1996-02       Impact factor: 3.500

4.  Studies into radiolytic decomposition of fluorine-18 labeled radiopharmaceuticals for positron emission tomography.

Authors:  Peter J H Scott; Brian G Hockley; Hank F Kung; Rajesh Manchanda; Wei Zhang; Michael R Kilbourn
Journal:  Appl Radiat Isot       Date:  2008-09-07       Impact factor: 1.513

5.  Toxicologic effects of a novel acyl-CoA:cholesterol acyltransferase inhibitor in cynomolgus monkeys.

Authors:  J F Reindel; M A Dominick; T M Bocan; A W Gough; E J McGuire
Journal:  Toxicol Pathol       Date:  1994 Sep-Oct       Impact factor: 1.902

6.  Myeloid Acat1/Soat1 KO attenuates pro-inflammatory responses in macrophages and protects against atherosclerosis in a model of advanced lesions.

Authors:  Elaina M Melton; Haibo Li; Jalen Benson; Paul Sohn; Li-Hao Huang; Bao-Liang Song; Bo-Liang Li; Catherine C Y Chang; Ta-Yuan Chang
Journal:  J Biol Chem       Date:  2019-09-08       Impact factor: 5.157

7.  Expression of ACAT-1 protein in human atherosclerotic lesions and cultured human monocytes-macrophages.

Authors:  A Miyazaki; N Sakashita; O Lee; K Takahashi; S Horiuchi; H Hakamata; P M Morganelli; C C Chang; T Y Chang
Journal:  Arterioscler Thromb Vasc Biol       Date:  1998-10       Impact factor: 8.311

8.  Copper-Mediated Radiofluorination of Arylstannanes with [18F]KF.

Authors:  Katarina J Makaravage; Allen F Brooks; Andrew V Mossine; Melanie S Sanford; Peter J H Scott
Journal:  Org Lett       Date:  2016-10-10       Impact factor: 6.005

Review 9.  Molecular imaging of atherosclerosis with integrated PET imaging.

Authors:  Basma Hammad; Nicholas R Evans; James H F Rudd; Ahmed Tawakol
Journal:  J Nucl Cardiol       Date:  2017-01-11       Impact factor: 5.952

10.  ATR-101, a selective ACAT1 inhibitor, decreases ACTH-stimulated cortisol concentrations in dogs with naturally occurring Cushing's syndrome.

Authors:  Daniel K Langlois; Michele C Fritz; William D Schall; N Bari Olivier; Rebecca C Smedley; Paul G Pearson; Marc B Bailie; Stephen W Hunt
Journal:  BMC Endocr Disord       Date:  2018-05-02       Impact factor: 2.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.